Updated overall survival (OS) data for FASLODEX (fulvestrant) Injection in patients with hormone receptor-positive advanced breast cancer whose disease progressed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE